I'm LongbridgeAI, I can summarize articles.Genprex announced that the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering Reqorsa Gene Therapy combined with PD-1 or PD-L1 antibodies to treat non-small cell and small cell lung cancers. This new patent extends Genprex’s international protections, reinforcing its intellectual property position for therapies tested in the Acclaim-3 clinical trial.
Genprex ( (GNPX) ) has shared an update.
On June 22, 2026, Genprex announced that the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering the use of Reqorsa Gene Therapy with PD-1 or PD-L1 antibodies to treat both non-small cell and small cell lung cancers. The new Canadian patent extends Genprex’s existing international protections for Reqorsa combinations, reinforcing its intellectual property position around therapeutic regimens being tested in the Acclaim-3 clinical trial and underscoring its strategic focus on lung cancer, a leading cause of cancer deaths in Canada.
More about Genprex
Genprex, Inc. is a biotechnology company focused on developing gene therapy-based treatments, with an emphasis on oncology and diabetes. Its lead candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is being developed in combination with approved targeted drugs and immunotherapies, particularly for lung cancers, to potentially enhance existing treatment regimens.
Average Trading Volume: 654,489
Technical Sentiment Signal: Sell
Current Market Cap: $6.47M
For a thorough assessment of GNPX stock, go to TipRanks’ Stock Analysis page.